Faeth Therapeutics Raises $47M in Series A Funding
Summary
The company intends to use the funds to advance its clinical trials that combine nutrient control, therapeutics and digital tools to inhibit cancer metabolism. The proceeds of the round will be used to support early phase clinical trials focusing on the safety of its approaches in cancer patients. Additionally, the funds will support the development of novel preclinical pipeline with its discovery platform, MetabOS™, which combines machine learning and functional genomics to uncover the precise nutrient vulnerabilities for a tumor based on genotype, organ of origin, and therapy, Led by CEO Anand Parikh and Chief Scientific Officer Oliver Maddocks, Faeth Therapeutics leverages an approach that includes precisely targeted nutrient control, therapeutics, and digital tools to support both the patient and clinician. Preclinical studies in organoid and mouse models demonstrate that precise control of molecules, including amino acids and sugar, can reduce tumor size and suppress growth to a similar extent as standard-of-care chemotherapies, and combining nutrient control with drugs is significantly more efficacious than either intervention alone. Faeth’s founding team also includes Sid Mukherjee, a Pulitzer Prize-winning oncologist and professor at Columbia University Irving Medical Center, and Lew Cantley, former Director of the Meyer Cancer Center at Weill Cornell Medicine and now a professor at the Dana-Farber Cancer Institute
Funding
Review available funding amount, funding date, investors, and linked company information related to Faeth Therapeutics Raises $47M in Series A Funding in the interactive ISVWorld profile.